Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Early Friday, Sarepta Therapeutics unveiled promising results for a gene therapy known as SRP-9003 in three patients with a form of muscular dystrophy — prodding Sarepta stock to pop.

Does This Beleaguered Biotech Stock Have A Winner In Gene Therapy?

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy (DMD) trial.

More Good News for Duchenne Muscular Dystophy Patients

-- Improvements on functional measures seen in all three participants --  -- Significant reduction in creatine kinase maintained over nine months --

Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

CAMBRIDGE, Mass., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty-seven individuals hired by Sarepta in September 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule  5635(c)(4)

The FDA decided to fast-track the approval for Exondys, however, it is unknown how much latitude it will continue to give the company.

Sarepta: Risks Are Priced In, Valuation Is Compelling

Regulators raised concerns with two of the company's drug candidates.

Here's Why Sarepta Therapeutics Dropped 39.4% in August

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Why Is Sarepta Therapeutics (SRPT) Down 33.1% Since Last Earnings Report?

CAMBRIDGE, Mass., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 11:05 a.m. ET. The fireside chat will be held at the Grand Hyatt New York in New York City, NY.

Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

Sarepta's CEO and another key board member continue to buy into the long-term prospects of the company.

After The Dust Has Settled, Key Sarepta Therapeutics Insiders Are Still Buying Shares And So Should Investors

Sarepta recently received a CRL for golodirsen in DMD. The CRL is a bit controversial because it pointed to pre-clinical data and potential injection site issues.

Sarepta: A Controversial CRL Provides Buying Opportunity

Align Technology

Iovance Biotherapeutics

Regeneron Pharmaceuticals

The more disruptive the market is, the more we look for companies that are not affected by the daily sturm and drang of the news cycle because they have supply chain issues in China.

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

Sarepta is down big this week on news that the Food and Drug Administration raised concerns about its New Drug Application.

We See Opportunity In Sarepta

Here's what bargain biotech shoppers need to know about Sarepta's future.

Is Sarepta Therapeutics a Bad News Buy?

Sarepta receives complete response letter for golodirsen in DMD, but safety issues cited should be corrected within the next few years.

Sarepta May Have Lost The Battle For Latest FDA Approval Of DMD Drug, But It Will Win The War

Sarepta Therapeutics stock continued a three-day tumble Thursday after the Food and Drug Administration rejected its newest Duchenne muscular dystrophy treatment, dubbed golodirsen.
The post Why Analysts Are Upbeat On Sarepta Despite A Notable FDA Rejection appeared first on Investor's Business Daily.

Why Analysts Are Upbeat On Sarepta Despite A Notable FDA Rejection

Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

Sarepta Therapeutics (NASDAQ:SRPT) was just hit with a hefty dose of regulatory reality.

FDA Rejection of Sarepta's Golodirsen Should Have Been Expected

The biotech is reeling following the thumbs-down for its experimental DMD drug golodirsen.

What's Next for Sarepta Therapeutics After Its Surprising FDA Rejection

Madison Square Garden

Hain Celestial Group

These stocks led the broader market lower.

Why Madison Square Garden, Hain Celestial Group, and Sarepta Therapeutics Slumped Today

Sarepta Therapeutics Inc (NASDAQ: SRPT)'s new drug application for its second Duchenne muscular dystrophy drug received a a complete response letter from the FDA on Monday.

Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy

Sarepta Therapeutics stock crashed Tuesday after the Food and Drug Administration left the biotech company twisting "in the wind" over its newest Duchenne muscular dystrophy treatment.
The post Why The FDA Left Sarepta To 'Twist In The Wind' Over Its Newest Drug appeared first on Investor's Business Daily.

Why The FDA Left Sarepta To 'Twist In The Wind' Over Its Newest Drug

The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

Sarepta Stock Falls as FDA Denies Approval to Golodirsen

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are tanking Tuesday morning as a binary event turned up a negative outcome for the company.

Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug

Sarepta Therapeutics stock toppled late Monday after the Food and Drug Administration rejected of the biotech company's latest Duchenne muscular dystrophy drug, dubbed golodirsen.
The post Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy Drug appeared first on Investor's Business Daily.

Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy Drug

Sarepta Therapeutics Inc. SRPT, -3.71% shares fell in the extended session Monday after the drug maker said the Food and Drug Administration raised concerns about its muscular dystrophy treatment.

News for Sarepta Therapeutics Stock (SRPT)